PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

Anti-Cancer Drugs

Volumn 25, Issue 10, 2014, Pages 1129-1140

  Xing, Xiaofang ^a   Zhang, Lianhai ^a   Wen, Xianzi ^a   Wang, Xiaohong ^a   Cheng, Xiaojing ^a   Du, Hong ^a   Hu, Ying ^a   Li, Lin ^a   Dong, Bin ^a   Li, Ziyu ^a   Ji, Jiafu ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Angiogenesis; Gastric cancer; Mammalian target of rapamycin inhibitor; Metastasis; Proliferation

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; F ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; ONCOPROTEIN; PURINE DERIVATIVE; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ACTIN FILAMENT; ADULT; ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CAPILLARY ENDOTHELIAL CELL; CELL COUNTING; CELL GROWTH; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; DRUG CYTOTOXICITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ADENOCARCINOMA; AGED; CELL MOTION; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION; VASCULARIZATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PURINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84921789603     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000148     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide. Lyon, France: International Agency for Research on Cancer; 2010.
2. Bouche O, Penault-Llorca F. HER2 and gastric cancer: A novel therapeutic target for trastuzumab. Bull Cancer 2010; 97:1429-1440.
3. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485:55-61.
4. Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab 2014; 19:373-379.
5. Korets SB, Czok S, Blank SV. Curtin JP.Schneider RJ. Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res 2011; 17:7518-7528.
6. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66:1203-1212.
7. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29:3733-3744.
8. Shor B, Gibbons JJ, Abraham R, Yu K. Targeting mTOR globally in cancer: Thinking beyond rapamycin. Cell Cycle 2009; 8:3831-3837.
9. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009; 15:1277-1287.
10. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009; 100:971-978.
11. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25:6436-6446.
12. Jhanwar-Uniyal M, Albert L, McKenna E, Karsy M, Rajdev P, Braun A, et al. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. Adv Enzyme Regul 2011; 51:164-170.
13. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-1128.
14. Gupta S, Hau AM, Beach JR, Harwalker J, Mantuano E, Gonias SL, et al. Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion. PLoS One 2013; 8:81081.
15. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009; 15:1821-1829.
16. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-2287.
17. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116:4560-4568.
18. Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv Exp Med Biol 2006; 587:309-327.
19. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg 2009; 6:47-55.
20. Bu Z, Ji J. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer. Curr Cancer Drug Targets 2013; 13:121-125.
21. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009; 8:567-572.
22. Gruppuso PA, Boylan JM, Sanders JA. The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle 2009; 10:1050-1058.
23. Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, et al. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer 2012; 12:86.
24. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, et al. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012; 120:2679-2689.
25. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, et al. Blocking on the CXCR4/mTOR signalling pathway induces the antimetastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 2008; 44:1022-1029.
26. Hong SM, Park CW, Cha HJ, Kwon JH, Yun YS, Lee NG, et al. Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma. Clin Exp Metastasis 2012; 30:177-187.
27. Gokmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat 2012; 136:673-682.
28. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 2008; 8:647-665.
29. Azim H, Azim HA Jr, Escudier B. Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol 2010; 5:269-280.
30. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8:851-864.
31. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2010; 12:21-35.
32. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 2009; 100:782-788.
33. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008; 23:1-9.